Loading stock data…
NTHI
$4.42-0.07 (-1.56%)
After Hours$4.42+0.00 (+0.00%)· Last close Jun 9
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeOnc Technologies Holdings, Inc. in the Healthcare sector is trading at $4.42 with a market capitalization of $113M. Wall Street consensus targets $16.00 (3 analysts), implying a +262.0% move over the next 12 months. The stock is currently near its 52-week low of $3.20, remaining 46.2% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 19 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +262.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 19) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.42
Potential Downside
0%
Whystock Fair Value$4.42
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$16.00+262.0%
Range$13.00 – $20.00
Fundamentals
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$113.16M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
292.04%
Volume
Today's trading volume
27,248
Recent News
NeOnc Technologies (NTHI) Could Be Targeting A Challenging Market With A Different Strategy
With a stock price of $4.64, NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) is among the 8 Best Up and Coming Penny Stocks to Buy Now. On May 19, Alliance Global initiated coverage of NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) with a Buy rating and a $13 price target. The firm highlighted the company’s focus on developing intranasally delivered small-molecule […]
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story. But here’s what you should actually be watching. Holders captured the move; new entrants face tougher math from here. The market cap sits at roughly $6.36 million, the company reported a Q1 2024 net loss ... Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
Insider Buys Additional US$185k In NeOnc Technologies Holdings Stock
Investors who take an interest in NeOnc Technologies Holdings, Inc. ( NASDAQ:NTHI ) should definitely note that the...
With 61% ownership, NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) insiders have a lot riding on the company's future
Key Insights Insiders appear to have a vested interest in NeOnc Technologies Holdings' growth, as seen by their...
AI and biotech take on brain cancer
You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (NTHI), about how the company defied a tough market to go public, secure a $50 million partnership in the Middle East, and join the Russell Microcap Index. Heshmatpour explains NeOnc’s focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC’s medical school, and how global clinical trials are expanding the company’s reach. The conversation also includes how AI and quantum computing could transform the biotech industry. It’s a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.